Topical Imiquimod in Primary Cutaneous Extramammary Paget’s Disease: A Systematic Review
Cancers · 30.11.2023 · 15 (23) · 5665
DOI: 10.3390/cancers15235665 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 30.11.2023. Verfasst von Fátima Mayo-Martínez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Extramammary Paget’s disease (EMPD) is subclinical in extent and multifocal in nature. There is no global consensus for treatment, so its management represents a challenge in clinical practice. Therefore, we conducted a systematic review through the main electronic databases to assess the effectiveness of topical imiquimod in cutaneous EMPD and to discuss its management. Finally, 24 studies involving a total of 233 EMPD patients treated with topical imiquimod were selected. The topical imiquimod response rate was 67%, and the complete response (CR) rate was 48%. Patients were treated with a three–four times a week regimen in most cases, ranging between 2 to 52 weeks. In addition, imiquimod was applied as an adjunctive treatment in 21 patients, achieving a CR rate of 71%. Consequently, imiquimod therapy could achieve a good response ratio as a first-line treatment, as adjuvant and neo-adjuvant therapy, and as a treatment for recurrent disease. The heterogeneity between studies and the lack of a control arm made it impossible to conduct a meta-analysis. To improve the quality of evidence on EMPD, multicenter studies are essential to collect a larger number of patients and, consequently, obtain high-quality evidence to standardize treatment. The Prospero registration number is CRD42023447443.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departments of Dermatology, Fundación Instituto Valenciano de Oncología, 46009 Valencia, Spain.
- Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain.
- Tekderma Instituto Dermatológico, Hospital Vithas Valencia 9 de Octubre, 46015 Valencia, Spain.
- Department of Physiotherapy, Catholic University of Valencia, 46001 Valencia, Spain.
- Institute of Sport, Nursing and Allied Health, University of Chichester, Chichester PO19 6PE, UK.
ORCID-Profile: Fátima Mayo-Martínez, Ruggero Moro, Iker Javier Bautista, Eduardo Nagore
Zitieren
APA
Mayo-Martínez, F., Moro, R., Millán-Esteban, D., Ríos-Viñuela, E., Bautista, I. J., Nagore, E., Sanmartín, O., & Llombart, B. (2023). Topical Imiquimod in Primary Cutaneous Extramammary Paget’s Disease: A Systematic Review. Cancers, 15(23), 5665. https://doi.org/10.3390/cancers15235665
Vancouver
Mayo-Martínez F, Moro R, Millán-Esteban D, Ríos-Viñuela E, Bautista IJ, Nagore E, et al. Topical Imiquimod in Primary Cutaneous Extramammary Paget’s Disease: A Systematic Review. Cancers. 2023;15(23):5665. doi:10.3390/cancers15235665
BibTeX
@article{MayoMartnez2023,
author = {Mayo-Martínez, Fátima and Moro, Ruggero and Millán-Esteban, David and Ríos-Viñuela, Elisa and Bautista, Iker Javier and Nagore, Eduardo and Sanmartín, Onofre and Llombart, Beatriz},
title = {Topical Imiquimod in Primary Cutaneous Extramammary Paget’s Disease: A Systematic Review},
journal = {Cancers},
year = {2023},
volume = {15},
number = {23},
pages = {5665},
doi = {10.3390/cancers15235665}
}
EUVIMED